Egrifta, With Help From Patient Testimonies, Gets Advisory Committee Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
Unanimous vote for Theratechnologies' HIV lipodystrophy drug by Endocrinologic and Metabolic Drugs Advisory Committee acknowledges need for post-marketing safety work.
You may also be interested in...
Delayed Egrifta Approval Brings Clean Label, No REMS For Theratechnologies
Tesamorelin becomes the first drug approved by FDA to treat HIV-related lipodystrophy.
Delayed Egrifta Approval Brings Clean Label, No REMS For Theratechnologies
Tesamorelin becomes the first drug approved by FDA to treat HIV-related lipodystrophy.
The Risks Of Surrogacy: Egrifta Faces Twofold Challenge At Advisory Committee
Theratechnologies will need to address FDA's concerns about whether a reduction of patients' visceral abdominal fat produced by the HIV lipodystrophy product has clinical meaning and is worth the risks.